About This Video
Telescope Innovations Corp. is a public company listed on the Canadian Securities Exchange stock market under the symbol TELI.
Telescope is a chemical technology company developing scalable, widely deployable synthetic processes to access pharmaceuticals for the treatment of mental health. Research and development efforts are focused on medicines from the under-utilized tryptamine class of compounds, leveraging innovative process chemistry to access novel molecules. Their aim is to bring modern chemical solutions to meet the most serious challenges in human health. In pursuit of this goal, they also develop tools to advance the global chemical manufacturing sector.
Learn more about Telescope Innovations Corp. at https://thecse.com/en/listings/technology/telescope-innovations-corp
Subscribe for more great CSE insights and interviews here: https://go.thecse.com/CSETV-Subscribe
STAY CONNECTED WITH THE CSE
=============================
- PODCAST: https://blog.thecse.com/cse-podcasts/
- INSTAGRAM: https://www.instagram.com/canadianexchange/
- LINKEDIN: https://ca.linkedin.com/company/canadian-securities-exchange
- FACEBOOK: https://www.facebook.com/CanadianSecuritiesExchange/
- TWITTER: https://twitter.com/CSE_News
- BLOG: https://blog.thecse.com/
- WEBSITE: https://thecse.com/
Read the TranscriptAuto-generated by YouTube; names and terms may be misspelled.
thank you for tuning in to another newly listed on the csc i'm a neil mall representing the canadian securities exchange and today i am talking to jason hein jason hein is the ceo of telescope innovations corp this company listed on the canadian securities exchange in september and jason is also a professor of chemistry at the university of british columbia jason thank you so much for your time today how are you doing
really well thanks for having me on the nail of course so jason i'm sure our audience just like myself is curious about the company telescope innovations corp tell us a little bit about what you do we're a chemical technologies company what we do is we've brought together a whole bunch of experience from my my academic background actually focusing on developing robotics and automation to study chemical reactions and
basically understand what makes them work what makes them not work really the the suite of technology we put together can best be thought of sort of at like building gps for a chemical reaction we can see inside the process and because of that we can make decisions about what we have to do to to guide it to the compound that we're looking to build so this is this is a radical change in sort
of how chemical manufacturing works because instead of sort of if you think a recipe mix it all together and you kind of hope you come up with a cake we can actually see what's happening step by step and then control the process to go where we want to go i i like that an analogy to simplify such a technical topic using cake what was the strategy behind taking this
company the public route so the main point was we've we've got the suite of technology and really it can attack a number of important problems so we focused right now on the psilocybin and psychedelic medicine space and because of that we really needed to access some public capital quickly and and particularly having access to capital markets through something like csc is a great way to take this this
really revolutionary technology and push it out to direct application very quickly right so this is this has been our number one point in addition the board and the people we have in our management side are really really deep experience in the in the capital markets and have been managing public companies for many years so it's the combination of this radical technology and an amazing marketing and strategy board
that means that this is the the right fit for how we want to grow the company perfect jason i actually do want to talk a little bit more about the team but let's start with your background obviously i mentioned earlier you are a professor of chemistry at the university of british columbia but how did you get into this space talk to our audience about your background yeah so i started
actually from the university of manitoba i started with a normal phd in chemistry but it was actually through my post-doc at with barry sharpless at the scripps research institute in san diego so i actually got to join barry's group right after he'd won the nobel prize in chemistry and it's it's through his training in tutelage that i really understood that what was missing about synthesis was this this gap was we didn't really know
what was happening as reactions were happening we're still groping around the dark even though this is an advanced field that led me to my academic career where i was building tools and applications in this space and as we started to grow that i actually started my pr my program here at university of british columbia we're now a 30 person group that actually brings together chemists computer scientists
mechatronic engineers really interdisciplinary but the the transition over to the company side is really because the things we build in this research space in order to really have meaningful application we need to reduce it to practice so that we can actually push it out to industry and the best vehicle to do that is through a spin-off and that's that's exactly where we sort of started in this space here
so jason you're obviously the right person you've got a strong background in this space are there any other key team members that the company has brought on board yeah absolutely so myself again i'm the one that's leading the charge right now but i've been lucky enough to first of all hire a number of my most experienced technicians and senior postdocs into the company as our sort of
founding members so these are people i have trained and they know this in in their dna but in addition barry sharpless has been retained as one of our our key advisors so and this is his experience spans 30 40 years with over 450 academic publications and 33 patents in addition we've also retained henry dubina henry actually was the recently the president of
network pluto autocam one of the largest instrumentation companies in the world and really a founder of things for enabling chemical technology so he's coming on as a senior advisor as well on the director's side we have andy robinson and robert mintak both of them have been providing leadership originally from the company called standard lithium and their background stretches of more than 20 plus years of building technology companies and
project management in addition one of our senior board members is ali pagman he has 20 plus years of experience in the investment banking and other sort of capital markets point and brings together sort of a really really good sort of access to possibly equity financing my next question what differentiates a company like telescope innovations core from some of your peers that are in the similar space
yeah and and to sort of frame it around our current charge into the the psilocybin space is a good way to sort of poke it so we're attacking this problem saying that what's necessary is clean efficient manufacturing routes to this this pharmaceutical access to that compound is the thing that's a major bottleneck in that entire space so it's not only just what molecule we're going to entertain as a molecule but but how you
get there and that how you get their question is exactly what we are best structured to sort of answer we've her to put that part this longer vision of being able to make the compound to actually use something that's an ip protected route and and to be able to scale that up so that it could actually meet the demands of that entire mental health space is is something that's
forefront what we're actually attacking but behind that right the technology we build is kind of our main dna right now we're focusing heavily on this space but there's an entire vertical based around the instrumentation where leadership from somebody like henry allows us to actually push this technology out as a separate whole vertical piece so i really see that what makes us different is it's what we do
and how we do it both of those two things are very novel got it now i'm sure investors and our audience members that are watching want to know if there are any milestones that you're able to talk about yeah absolutely so we're we're coming up onto our final conversion of our pct application that's our manufacturing route to psilocybin that should be filed later this year we also have a number of agreements
in place that joint development agreements for our technology which would look like basically proof of concept demonstration where this would be vended into major pharmaceutical manufacturing so those could be places like merck and pfizer as as possible places where this technology would be deployed for actual sort of live testing and use and scale right so this allows us to prove out what we've been
sort of doing in a real world environment very interesting and i'm sure that as the team moves forward there's going to be a lot more to talk about where can our viewers go to you know sign up for your press releases read up on your team and get more details on on the company so check out telescopeinnovations.com that's our website and then we'll keep it up to
date with our press releases and stuff if you're interested in more information info telescope in dot com is our is our email address and and yeah happy to sign you up at that point for further information perfect jason i really appreciate you taking some time today to come talk and educate not only myself but our audience members on a company like telescope innovations can't wait to see what you
guys have in store in the coming months that are left in this year and and beyond in 2022 i'll definitely be keeping a close eye on what you guys are doing and to everybody watching you've been watching a newly listed on the csc clip with jason hein jason is the ceo of telescope innovations corp he's also the professor of chemistry at the university of british columbia and of course i'm a
neil mall with the canadian securities exchange thank you for tuning in
thank you for tuning in to another newly listed on the csc please feel free to hit like and share this content and hit subscribe if you haven't already



